Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast and R-CHOP in high-risk DLBCL
NCT03458546Phase 1Completed
- Sponsor
- UT Health San Antonio
- Start
- May 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of roflumilast in diffuse large B-cell lymphoma (DLBCL), sponsored by UT Health San Antonio. Started May 2018; status: completed.
02
Drugs
roflumilast
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03458546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03458546.